RecruitingNCT02414347

F 18 T807 Tau PET Imaging of Alzheimer's Disease

F 18 T807 Tau PET Imaging of Alzheimer's Disease [IND# 123119] Protocol A


Sponsor

Tammie L. S. Benzinger, MD, PhD

Enrollment

900 participants

Start Date

Oct 23, 2014

Study Type

OBSERVATIONAL

Conditions

Summary

A single-center, open-label baseline controlled imaging study designed to assess whether brain tau fibril uptake of flortaucipir as measured by PET correlates with cognitive status of individuals with and without brain tau fibrils.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using a specialized brain scan (called F18-T807 tau PET imaging) that detects abnormal protein buildup in the brain linked to Alzheimer's disease, to better understand how early this buildup appears and how it relates to memory and thinking changes. **You may be eligible if...** - You are 18 years of age or older - You have normal thinking and memory, or only mild memory difficulties - You are able and willing to undergo PET and MRI brain scans, including an injection of a small amount of radioactive tracer - Women who have not yet reached menopause will need to take a pregnancy test **You may NOT be eligible if...** - You have a medical condition that would make scanning unsafe or would interfere with results - You take medications or have heart conditions involving abnormal heart rhythms - You are allergic to the imaging agent used in the scan - You cannot lie still in an MRI or PET scanner, or have severe claustrophobia - You have a pacemaker or other metal implant that prevents MRI - You are currently pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGF 18 T807

Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.


Locations(1)

Washington University School of Medicine

St Louis, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02414347


Related Trials